patient's optimal dose of oral medication for longterm antiarrhythmic treatment must be determined by therapeutic monitoring, usually frequent measurements of serum drug concentration; however, such measurements are costly and time-consuming. In previous studies, clinical administration of antiarrhythmic agents was found to cause changes in signal-averaged electrocardiographic (SAECG) parameters 1 and each antiarrhythmic agent affected the electrocardiographic (ECG) variables in a different manner. 2,3 Also, it has been reported that SAECG is more sensitive than a standard ECG in detecting the changes in QRS duration resulting from administration of class I antiarrhythmic drugs. 4,11 Therefore, the purposes of the present study were to compare the ECG changes caused by administration of 3 class I antiarrhythmic agents (flecainide, pilsicainide and, pirmenol), and to identify the SAECG parameters that might be used to estimate changes in serum concentration of antiarrhythmic agents during monitoring for long-term therapy.
cainide; 12, pirmenol) who had symptomatic ventricular or supraventricular arrhythmias. The underlying heart diseases included coronary artery disease (CAD), hypertensive heart disease, cardiomyopathy and valvular disease, but in some cases there was no underlying heart disease ( Table 1) . Of those with CAD, none had unstable angina. Three patients had a history of old myocardial infarction, but their cardiac function were not suppressed. No significant difference was seen in the distribution of diagnoses among the groups treated with each of the 3 drugs. Mean age was 63±17 years. Patients with bundle branch block or other conduction disturbances were excluded.
Informed consent was obtained from the patients.
Measurement of SAECG Parameters
We used a NEC-DP 1100 signal processor for recording and measuring 3 conventional SAECG parameters: (1) the duration of the total filtered QRS (f-QRS); (2) the duration of the low-amplitude (<40 V) signal at the terminal portion of the QRS complex (LAS40); and (3) the root mean square voltage of the last 40 ms of the QRS complex (RMS40). The SAECG was recorded in the resting state, and the heart rate during recordings remained within the range of 60-90 beats/min in all patients.
The initial SAECG recording was made before beginning antiarrhythmic therapy, followed by a second recording at 1 month after initiation of drug administration to ensure steady-state conditions. Patients were treated with standard recommended therapeutic doses of each antiarrhythmic drug, but these were sometimes modified according to the age and weight of the patient, as well as by the severity of arrhythmias. At the time of the second recording, serum drug concentrations had been determined. Two subsequent SAECG recordings were accompanied by blood sampling to determine the changes in the serum concentrations of the drugs. The time interval after the second SAECG recording at which these later paired examinations were carried out ranged from 2 to 4 months.
The patients were followed up at our outpatient clinic and the blood samples were usually taken within 2-4 h of drug administration.
Statistical Analysis
Data are given as mean ± SD. Paired two-tailed Student's t-Tests were used to compare continuous variables. P values less than 0.05 were considered to indicate significance.
Results

Effects of the Drugs on SAECG Parameters
f-QRS Flecainide, pilsicainide and pirmenol all prolonged the f-QRS significantly (Tables 2-4) .
LAS40 All 3 drugs significantly prolonged LAS40, but Table 3 Effect of Pilsicainide on SAECG Parameters particularly pilsicainide (Tables 2-4) . RMS40 RMS40 was decreased equally by flecainide and pirmenol, and pilsicainide had a minimal effect only (Tables 2-4) .
Mean serum concentrations at 1 month after beginning therapy were 218 ng/ml for flecainide, 480 ng/ml for pilsicainide, and 514 ng/ml for pirmenol; these concentrations were within the therapeutic range in all patients.
Changes in Serum Drug Concentration and the SAECG Parameters
Serum concentrations of flecainide correlated strongly with change in f-QRS (r=0.91; Fig 1) as did those of pilsicainide (r=0.70; Fig 2) and pirmenol (r=0.61; Fig 3) . The other 2 SAECG parameters ( RMS40 and LAS40) did not show a significant correlation with the serum concentration of any of the 3 antiarrhythmic agents.
Discussion
Monitoring of the serum concentration of antiarrhythmic agents by repeated blood samples is costly, and unpleasant for patients. In the present study, with flecainide in particular, we observed a significant correlation between serum drug concentration and changes in the f-QRS on SAECG.
In clinical practice, prolongation or shortening of the f-QRS can be taken to suggest excessively high or low concentrations of flecainide, and to indicate the need for a blood sample to determine the serum drug concentration. On the other hand, if the f-QRS is stable, frequent serum determinations probably are unnecessary.
The mechanism of prolongation of the f-QRS by class I antiarrhythmic drugs is thought to be a potent blockade of the sodium channels that slows phase 0 depolarization and intraventricular conduction. 5 The rate at which these drugs bind to or dissociate from the sodium channels is sufficiently slow for a strong blocking action to be exerted, even during sinus rhythm. However, the kinetics of each of these drugs (and especially the affinity for the Na + channel) differ. Flecainide 6 and pilsicainide exhibit very slow kinetics, whereas pirmenol has different features, including a shorter time constant, 1 which indicates that presumption of the serum concentration of pirmenol during sinus rhythm will be more difficult than with the other 2 drugs. Furthermore, our study results imply that of the 3 class I antiarrhythmic agents we studied, flecainide has the most stable concentration, which is surprising considering that it has been found to have nonlinear kinetics even in patients with normal kidney and liver function. 7 Therefore, even in patients with normal renal function, and without heart failure, chronic administration of the drug may lead to its unexpected accumulation, probably because of genetically poor metabolism, so monitoring the plasma concentration is necessary. 7 Most of the class Ia and class Ic antiarrhythmic drugs are excreted mainly by the kidney and therefore their use in patients with impaired renal function must be carefully monitored by clinicians. 8 The main limitation of the present study is that SAECG parameters can be affected by many factors not associated with antiarrhythmic therapy, such as transient ischemia, changes in autonomic tone, and conduction disturbances. 9, 10 However, we conclude that changes in the serum concentration of flecainide, pilsicainide and pirmenol can be estimated from changes in the duration of f-QRS, which is prolonged in a dose-dependent manner, during SAECG recording. Such a screening test could improve the therapeutic monitoring of these antiarrhythmic agents by reducing the frequency of serum drug assays.
